Biography

Dr.Troendle has been the President since having founded Medpace in 1992. His vision and strategic direction for Medpace has been a key factor in the growth of the company as a pre-eminent full-service CRO - serving sponsors in both drug and device development in over 45 countries. He previously worked for Sandoz (Novartis) where he was responsible for the clinical development of lipid altering agents. His past experience as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA gives him insight into the regulatory environment for development of drugs in the metabolic and cardiovascular fields. Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine.